Stellus Capital Investment Corporation (SCM) Q2 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call presents a mixed picture: there is a decrease in NAV and net investment income, but an optimistic outlook on equity gains and portfolio growth. The Q&A reveals confidence in handling nonaccruals and growing the portfolio, yet admits to uncertainties. No major positive catalysts like partnerships or strong guidance were announced. The dividend remains unchanged, and there's no significant negative sentiment from analysts. Given the lack of a clear positive or negative catalyst, the stock price is likely to remain stable, resulting in a neutral sentiment rating.
Key Financial Performance
GAAP Net Investment Income $0.34 per share, with a year-over-year change not explicitly mentioned. The decrease in net asset value per share by $0.04 during the quarter was due to the reduction in spillover income.
Core Net Investment Income $0.35 per share, excluding estimated excise taxes. Year-over-year change not explicitly mentioned.
Net Asset Value (NAV) per Share Decreased by $0.04 during the quarter due to the reduction in spillover income. Year-over-year change not explicitly mentioned.
Investment Portfolio at Fair Value $985.9 million across 112 portfolio companies, slightly down from $991 million across 110 companies as of March 31, 2025. The decrease was due to repayments and other investment activities.
New Investments $15.4 million invested in 3 new portfolio companies, with $7.4 million in other investment activity at par. Year-over-year change not explicitly mentioned.
Repayments Two full repayments totaling $21.7 million, one equity realization totaling $500,000 (resulting in a realized gain of $200,000), and $10.4 million of other repayments, all at par. Year-over-year change not explicitly mentioned.
Loans on Nonaccrual Loans to 5 portfolio companies on nonaccrual, comprising 6.8% of the total cost and 3.8% of the fair value of the total loan portfolio. This represents a decrease from the prior quarter.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Portfolio Growth: Investment activity has increased significantly over the past 30 days, with $26 million of new fundings since June 30, 2025. The portfolio now stands at approximately $1 billion across 113 companies, the largest number to date.
M&A Activity: M&A activity is picking up, with expectations of more equity realizations over the next 5 months. Estimated proceeds are $12 million with approximately $10 million in gains.
Investment Portfolio: The investment portfolio at fair value is $985.9 million across 112 portfolio companies as of June 30, 2025. During the quarter, $15.4 million was invested in 3 new portfolio companies, and $7.4 million was allocated to other investment activities at par.
Repayments and Realizations: Received two full repayments totaling $21.7 million, one equity realization of $500,000 with a realized gain of $200,000, and $10.4 million of other repayments, all at par.
Loan Quality: 98% of loans are secured, and 91% are priced at floating rates. Loans to 5 portfolio companies are on nonaccrual, comprising 6.8% of the total cost and 3.8% of the fair value of the total loan portfolio, representing a decrease from the prior quarter.
SBIC III License: Received a greenlight letter from the Small Business Administration for Stellus Capital SBIC III, an important step toward obtaining a license. Plans to draw new leverage under the SBIC III license to fund qualifying portfolio company investments as existing debentures are repaid.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Net Asset Value (NAV) Decrease: The net asset value per share decreased by $0.04 during the quarter due to the reduction in spillover income, which could indicate challenges in maintaining consistent income levels.
Nonaccrual Loans: Currently, loans to 5 portfolio companies are on nonaccrual, comprising 6.8% of the total cost and 3.8% of the fair value of the total loan portfolio. This represents a risk to income generation and asset quality.
Portfolio Companies Not Meeting Plan: 16% of the portfolio is marked at an investment category of 3 or below, meaning these companies are not meeting plan or expectations, which could impact overall portfolio performance.
Dependence on Private Equity Backing: All but one of the portfolio companies are backed by private equity firms, which could pose a risk if private equity markets face downturns or challenges.
Regulatory Uncertainty with SBIC III License: While the company has received a greenlight letter for the SBIC III license, the license is not guaranteed, which could impact future leverage and funding capabilities.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Portfolio Growth: Investment activity has picked up meaningfully over the past 30 days. The company expects the second half of the year to be busy, with $26 million of new fundings since June 30. The portfolio now stands at approximately $1 billion with 113 companies, the largest number to date. Based on new fundings and repayments, the portfolio is expected to end the quarter at about the same level.
Equity Realizations: With M&A activity picking up, the company expects to see more equity realizations over the next 5 months. The best estimate is $12 million of proceeds and approximately $10 million of gains.
Dividends: The company declared a dividend for the third quarter of $0.40 per share, payable monthly. The fourth quarter is also expected to maintain this $0.40 per share rate, subject to Board approval.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
Dividends paid since IPO: $306 million, representing $17.35 per share to an investor in the IPO in November 2012.
Third quarter dividend: Declared at $0.40 per share, payable monthly.
Fourth quarter dividend expectation: Expected to be at $0.40 per share, payable monthly, subject to Board approval.
Shares issued under ATM program (Q2 2025): Approximately 300,000 shares for $3.9 million of proceeds.
Shares issued under ATM program (Year-to-date): Approximately 900,000 shares for $13.2 million of proceeds, all issuances above net asset value.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:The EPS is not covering the dividend for the last few quarters. How much spillover is there left over? And what's the strategy in terms of increasing your leverage to cover the dividend?
A:The company has just under $45 million of spillover this year, which is being worked off through the dividend. For next year, the spillover is expected to be about $38 million. Regarding leverage, the company is currently running at about 0.9x on a regulatory test and 1.7x for GAAP. The target leverage is about 1:1 on the regulatory test, and there is no intention to change this in the near term. The company has the capacity to increase leverage through its bank facility and expects to grow its portfolio by $50 million to $75 million over time.
Q:For the SBIC III license, how much of your deal flow is eligible for the SBIC? And how quickly do you think you can fill that?
A:Historically, roughly half of the deal flow qualifies for the SBIC, making it a meaningful part of the company's operations. The company anticipates being able to ramp this up quickly once approved.
Q:How is the pipeline looking for the remainder of the year and where are you seeing opportunities, whether that's new or add-on investments?
A:There has been a significant pickup in M&A activity since July 4, with private equity firms becoming more active. The pipeline typically includes 10 actionable opportunities at a time, with 5 to 7 new opportunities per week. The company expects to grow its portfolio by the end of the year, despite slower repayments earlier in the year.
Q:Any insight into potential resolutions or progress being made with the current nonaccrual list?
A:The company continues to work through the nonaccrual list, with private equity firms backing the companies. No new nonaccruals were added this quarter. The company is optimistic about resolving these issues over time and is prepared to get more involved if necessary.
Q:What is the level of confidence on realizing $12 million in proceeds and $10 million in gains in the second half of the year?
A:The company is fairly confident, as the businesses in question are actively being marketed and are well-performing. However, there is always a possibility of delays, especially for equity-only positions.
Q:How much of the portfolio rated 3 or lower (not meeting plan) are you seriously nervous about?
A:By definition, a rating of 3 means the company expects to receive all principal and associated income. The company is not seriously nervous about these investments as they expect full recovery.
Q:How much uncertainty is there in growing the portfolio by year-end given the pipeline and timing?
A:The pipeline is robust, with many opportunities having a 75% or higher probability of closing. The company expects to grow the portfolio by year-end, although repayments may sometimes occur more quickly than new fundings.
Q:Review of Unclear Management Responses
A:Management avoided providing specific details on the timing and certainty of resolving the nonaccrual list, using general statements about private equity backing and ongoing efforts. Additionally, while they expressed confidence in realizing gains and growing the portfolio, they acknowledged uncertainties without providing concrete timelines or guarantees.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Associates Inc
CEO CFO
CFO Treasurer
Chairman President
Co Inc
Division Conference
Division Dodd
Division Justin
Dodd Raymond
ET lady
Hartung Marca
Inc Research
Instructions reminder
Investment Thomsen
Justin Hartung
LLC Research
Marca Lucid
Markets LLC
Nolan Ladenburg
Officer Whitbread
Patrick Nolan
President CEO
Raymond Associates
Research Division
SBIC III
Secretary Chief
Thalmann Co
Thomsen Chairman
license
portfolio investment
SCM Transcript
Stellus Capital Investment Corporation (SCM) Q1 2026 Earnings Call Transcript
Positive5-12
The earnings call highlights a strong financial performance with a 15% increase in net investment income and a 10% growth in portfolio size. The share buyback program and potential partnership with Ridgepost Capital add further positive sentiment. Despite a slight decrease in NAV per share, the overall outlook and strategic initiatives suggest a positive stock price movement in the short term.
Stellus Capital Investment Corporation (SCM) Q4 2025 Earnings Call Transcript
Unknown3-12
The earnings call presents a mixed outlook. The stock repurchase program and stable income metrics are positive, but concerns over nonaccrual loans and NAV decline offset these. The Q&A reveals management's cautious stance on leverage and uncertain timelines for resolving stressed assets, indicating potential risks. The buyback and dividend declaration could stabilize the stock price, but lack of clear guidance and unresolved nonaccruals suggest limited upside potential. Overall, the sentiment is neutral, reflecting a balance of positive shareholder returns and underlying financial challenges.
Stellus Capital Investment Corporation (SCM) Q3 2025 Earnings Call Transcript
Unknown11-12
The earnings call presents a mixed picture. Financial performance is stable, with no significant changes in net income or realized gains. The portfolio has grown, and the company has managed to reduce credit facility costs. However, the decrease in NAV and issuance of new shares could concern investors. The Q&A section indicates stability in the portfolio, but unclear responses on the SBA license timeline and spread dynamics add uncertainty. Overall, the neutral sentiment reflects stable but unexciting financial health and market strategy, with no strong catalysts for significant stock price movement.
Stellus Capital Investment Corporation (SCM) Q2 2025 Earnings Call Transcript
Unknown8-7
The earnings call presents a mixed picture: there is a decrease in NAV and net investment income, but an optimistic outlook on equity gains and portfolio growth. The Q&A reveals confidence in handling nonaccruals and growing the portfolio, yet admits to uncertainties. No major positive catalysts like partnerships or strong guidance were announced. The dividend remains unchanged, and there's no significant negative sentiment from analysts. Given the lack of a clear positive or negative catalyst, the stock price is likely to remain stable, resulting in a neutral sentiment rating.
SCM Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
